Vanda Pharmaceuticals Inc

NASDAQ:VNDAUnited States

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Contact Information

Headquarters

SUITE 300E, 2200 PENNSYLVANIA AVE NWWASHINGTON, DC, United States 20037

Phone

202-734-3400

Fax

202-296-1450

Executives

Chairman of the Board, President, Chief Executive Officer

Mihael Polymeropoulos

Chief Financial Officer, Senior Vice President, Treasurer

Kevin Moran

Senior Vice President, Chief Marketing Officer

Joakim Wijkstrom

Senior Vice President, General Counsel, Secretary

Timothy Williams

Senior Vice President - Business Development

Gunther Birznieks